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In the last decades we have witnessed a dramatic increase in infections caused by 
multidrug-resistant bacteria (MDRB). Organizations such as the European Center for Disease 
Prevention and Control (ECDC) and the World Health Organization (WHO) consider these 
infections as an emerging global disease and a major public health problem. Although the 
development of new antibacterial drugs seems to have reached a dead-end, potential new 
therapeutic strategies can be pursued [1]. Recently, WHO has reported a list of antibiotic 
resistant bacteria to guide the investigation, discovery and development of new antibiotics, 
mentioning as priority # 1 (critical) those Gram-negative bacilli such as Acinetobacter 
baumannii, Pseudomonas aeruginosa and 3rd generation cephalosporin and/or carbapenem 
resistant Enterobacteriaceae [2]. 
In recent years, measures are taken to control the emergence and spread of multi-
resistant bacteria (Figure) as well as to encourage the pharmaceutical industry to design and 
develop new antibiotics or new therapeutic strategies [3].  
In the nosocomial setting the control of the spread of MDRB is a crucial issue to 
prevent further infections. Patients colonized with MDRB can serve as reservoir for further 
dissemination of these bacteria and even be on risk to develop an infection caused by these 
bacteria. Although spontaneous loss of some of these MDRB can occur, selective digestive 
decontamination (SDD) with specific antibiotics has been used to decolonize the intestinal 
tract, eliminating MDRB. However, there is evidence both in favour and against this approach 
[4-8]. 
There are a couple of alternatives which may be useful to eliminate MDRB from the 
intestinal tract: 1. The use of “healthy” microbiota or faecal microbiota transplantation (FMT) 
to displace the MDRB, and 2. The use of the CRISPR-Cas system to specifically eliminate the 
gene(s) encoding resistant determinant(s).  
The use of faecal microbiota transplantation in the decolonization of MDRB have been 
reported, showing an effect in some patients in whom the elimination of MDRB was successful 
and others have not [9-17] (See Table). In a recent clinical trial performed by Bilinski and 
colleagues [17] on the use of FMT in patients with hematological diseases colonized with 
MDRB, complete MDRB decolonization after FMT was reached in 15/20 (75%). Overall, 
although it seems that the use of FMT to eliminate MDRB from intestinal tract is a promising 
strategy, several aspects should be taken into account. How many times should FMT be 
performed? What will the impact of using FMT in healthy people just to eliminate MDRB be? 
Would it be as successful as in patients? What is the best way of administration? FMT may also 
have an impact on factors beyond intestinal homeostasis such as the function of the immune 
system or the metabolic and neuropsychological health of the recipients [18]. In the future it 
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will likely be possible to design synthetic antimicrobial susceptible microbiota to be used in the 
FMT.  
The discovery of the clustered regularly interspaced short palindromic repeats and 
their associated proteins Cas (CRISPR-Cas system) is a cutting-edge technology that has 
different applications. One of this application is its use as a system to knock-out a specific 
bacterial gene, since CRISPR induces double stranded breaks. In this sense, CRISPR-Cas has 
been used to target specific genes for resistance located in plasmids. Knocking out these genes 
can re-establish the susceptibility of the bacteria to the antibiotic [19-22]. The major limitation 
is the delivery of the genetic construct to the bacteria. At present, it can be achieved using 
bacteriophages or plasmids transmissible by transduction or conjugation, respectively. Citorik 
et al. [19] used M13-derived phagemids encoding the genes of the CRISPR-Cas system. A 
phagemid is an engineered bacteriophage derived from a phage and a plasmid. This phagemid 
can be packaged into phage particles and used to deliver CRISR-Cas to the bacteria. The 
authors generated a genetic construct containing two spacers (“spacer” is the sequence in the 
CRISPR-Cas system which defines the genomic target to be modified) to target the blaNDM-1 and 
blaSHV-18 genes and observed a reduction of 2- to 3-log10 in viable Escherichia coli cells carrying 
plasmid containing the blaNDM-1 or blaSHV-18 genes but not in the wild type strain.  
Similarly, Yosef et al. [21] engineered a temperate λ prophage to carry the CRISPR-Cas 
system encoding spacers that target the blaNDM-1 and blaCTX-M-15 genes. The authors also found 
that lysogenic phage carrying CRISPR confer lytic phage resistance. An advantage is that the 
CRISPR-Cas system allows multiplexing against different targets, enabling simultaneous 
targeting of various resistance genes. Would this approach be efficacious in removing resistant 
genes from MDR bacteria found in the intestinal microbiota? The main limitation is to have a 
collection of appropriate temperate phages designed against multiple resistance genes and 
that resistance gene carried by the bacteria should be known. At present this is feasible. 
Phages seem to be well-tolerated when orally administered. Oral phage therapy for targeting 
bacteria located in the intestinal tract has been successfully used. In order to use the CRISPR-
Cas approach in vivo, the stomach must first be passed since deactivation of bacteriophages by 
acid may occur. Further investigation is needed to determine how this can be achieved in 
order for the phages to reach to the intestinal tract and still be active as well as establish the 
optimal doses to be used. One of the main advantages of this approach is that the 
susceptibility to antibiotics can be restored without compromising the normal microbiota of 
the individual. 
The development of either of these two approaches to an extent to which they can be 
efficiently and safely used to eliminate MDRB from the intestinal tract or any other location 
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would be a revolution in the battle against the threat of the antimicrobial resistance. They 
could be applied to patients carrying MDRB in different settings to prevent subsequent 
infections by these MDRB and dissemination of the MDR strain as well as to people returning 
from a trip to a country with a higher prevalence of MDRB and who have a high probability of 
carrying these bacteria in the intestinal tract and transferring the bacteria to relatives living in 
the same house [23]. In addition, they could be applied to animals since they have shown to 
play an important role as reservoirs of MDRBs. In conclusion, I am very optimistic about the 
use of these two approaches to combat antimicrobial resistance. In an ideal situation, it would 
be possible to use either “natural” or synthetic FMT to restore the disturbed microbiota, 
whereas CRISPR-Cas could be used to specifically sensitize resistant bacteria. 
Whatever the future may hold, it will certainly be interesting to watch and participate 
in the advancement of these two approaches in containing antimicrobial resistance. 
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GLOBAL 
HEALTH-CARE 
   CENTERS COMMUNITY 
NATIONAL-WIDE INTERNATIONAL-WIDE 
 General Population  
 Adhere strictly to therapeutic schemes 
 Respect proper treatment duration  
 Avoid self-medication with antibiotics 
 Proper cooking and handling of food 
 Hand-washing, when: 
 Before eating 
 Before and after touching a sick person 
 After using the bathroom 
 After touching an animal or handle animal waste 
 After handling rubbish 
 After being in places frequented by many people 
(example: public transportation) 
 Pharmacists 
 Reject to sale without prescription 
 Inform patients about when are  antibiotics 
needed, how to take them correctly and 
the consequences of a misuse. 
 Medical doctors 
 Practice safe prescription of antibiotics 
 Use of point-of-care tools to ensure when 
are antibiotics  needed 
 Veterinarians 
 Reduce the use of antibiotics in l ivestock   
 Avoid using antibiotics as prophylaxis 
 Provide veterinarians with latest 
information regarding antimicrobial 
resistance 
 Sensitization of resistant bacteria 
 Antimicrobial resistance surveillance at a national level 
 Antibiotic consumption at a national level 
 Implementation of action plan in each country in terms of 
Education  strategies among General Population as well as 
among Health specialists and Veterinarians 
 Antimicrobial stewardship 
 Leadership commitment and appointing AS team 
 Rapid and affordable diagnostic (Diagnostic stewardship) 
 Systematic evaluation of on-going treatment 
 Monitoring antibiotic prescribing and resistance patterns 
 Reporting information on antibiotic use and resistance  
 Education of cl inicians about resistance and optimal prescribing 
 Control 
    Active screening of contacts of MDR-GNB patients should be  
                        decided on the background of prevalence  in individual hospitals. 
    Screening of patients upon admission 
    Barrier isolation and isolation in single rooms or cohort                       
         isolation are implemented on the basis of inpatient risk areas. 
    Hand hygiene 
    Environmental cleaning 
    Decolonization of the MDRB or or sensitization of resistant bacteria 
How to diminish the emergence and spread of antimicrobial resistance bacteria? 
 Antimicrobial resistance surveillance at an 
international level 
 Antibiotic consumption at an international level 
 Defining integrated plans at a global level 
Table. Use of FMT for patients with intestinal tract colonization with resistant bacteria. 
 
 
Design of the 
study Nº Patients Bacteria targeted Intervention used % of success 
Length of 
follow up Ref. 
Case report 1 ESBL-producing E.coli FMT by naso-duodenal tube 
ESBL-E.coli negative in stool 
after 2 week 
1,2,4 and 12 
weeks 9 
Case report 1 Several MDROs FMT by colonoscopy Success 25 month 10 
Case report 1 VRE FMT by naso-duodenal tube 
Relative abundance of VRE 
(84%) before FMT 
     (24%) after 3 week 
     (0.2%) after 7 month 
1, 3 weeks and 
7 months 11 
Case report 1 OXA-48 producing Klebsiella pneumoniae 
FMT by naso-
duodenal tube Success 7 and 14 days 12 
Case report 1 VIM-1 producing Klebsiella pneumoniae Colonoscopy Success 
1 and 6 weeks 
and 6 months 13 
Case report 1 ESBL-producing E.coli FMT by naso-duodenal tube No success 
1 week to 3 
month 14 
Prospective single-
centre study* 11 VRE FMT via enema 72.7% 
7, 30, and 60 
days and 6 
months 
15 
Pilot prospective 
multicentre study 8 CRE and VRE 
FMT by naso-
duodenal tube 
25% (1st month) 
37.5% (3rd month) 1 and 3 month 16 
Prospective single-
centre study 20 Several MDROs 
FMT by naso-
duodenal tube 
75% (1 month) 
93% (6 month) 1 and 6 months 17 
 
* Stool VRE clearance in a post hoc analysis of the Phase 2 PUNCH CD study assessing a microbiota-based drug for recurrent Clostridium difficile infection. 
 
 
 
